Bladder Cancer News
A high monocyte-to-lymphocyte ratio and a high platelet-to-lymphocyte ratio were predictive of poor OS in patients with advanced gallbladder cancer treated with chemotherapy.
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
New evidence suggests variation in the bacterial composition of urine is associated with response BCG among patients with non-muscle-invasive bladder cancer.
Researchers found no significant difference in 30-day postoperative complications between patients who received neoadjuvant chemotherapy and those who did not.
An established chemoradiation regimen is compared with gemcitabine and once-daily radiation in the selective bladder-sparing treatment of muscle-invasive bladder cancer.
Older patients should be routinely assessed prior to radical cystectomy to guide both
preoperative and postoperative care.
Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.
Researchers found a microRNA signature in urine that can predict the presence of bladder cancer, advancing the idea of a noninvasive diagnostic test.
Researchers clarified the role of miR-125a-5p in bladder cancer, showing that it inhibits bladder cancer progression by targeting oncogene FUT4.
A retrospective study found EGFR and HER2 overexpression associated with clinical features, such as tumor stage and tumor recurrence, in bladder cancer tissue.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Patients at VA facilities with high-risk early-stage bladder cancer tend to have cystoscopic surveillance at frequencies similar to those with low-risk disease.
Treatment with NAC did not transform the prevailing subtype in bladder cancer — instead, shifts in cancer subtype were attributed to tumor plasticity.
Researchers propose a treatment algorithm to clarify treatment options beyond the first line for metastatic urothelial carcinoma of the bladder.
BCG shortages did not appear to influence the incidence of radical cystectomy, but evidence of drug rationing was revealed.
Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.
Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.